FI4076461T3 - Lumateperoni käytettäväksi skitsofrenian hoidossa - Google Patents

Lumateperoni käytettäväksi skitsofrenian hoidossa

Info

Publication number
FI4076461T3
FI4076461T3 FIEP20900863.0T FI20900863T FI4076461T3 FI 4076461 T3 FI4076461 T3 FI 4076461T3 FI 20900863 T FI20900863 T FI 20900863T FI 4076461 T3 FI4076461 T3 FI 4076461T3
Authority
FI
Finland
Prior art keywords
lumateperone
patient
use according
treatment
atypical antipsychotic
Prior art date
Application number
FIEP20900863.0T
Other languages
English (en)
Finnish (fi)
Inventor
Robert E Davis
Kimberly Vanover
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Application granted granted Critical
Publication of FI4076461T3 publication Critical patent/FI4076461T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FIEP20900863.0T 2019-12-19 2020-12-18 Lumateperoni käytettäväksi skitsofrenian hoidossa FI4076461T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962950828P 2019-12-19 2019-12-19
PCT/US2020/066224 WO2021127572A1 (en) 2019-12-19 2020-12-18 Methods of schizophrenia treatment

Publications (1)

Publication Number Publication Date
FI4076461T3 true FI4076461T3 (fi) 2026-03-24

Family

ID=76437353

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP20900863.0T FI4076461T3 (fi) 2019-12-19 2020-12-18 Lumateperoni käytettäväksi skitsofrenian hoidossa

Country Status (14)

Country Link
US (1) US20210186962A1 (enExample)
EP (2) EP4744678A3 (enExample)
JP (2) JP7727634B2 (enExample)
DK (1) DK4076461T3 (enExample)
ES (1) ES3067760T3 (enExample)
FI (1) FI4076461T3 (enExample)
HR (1) HRP20260406T1 (enExample)
LT (1) LT4076461T (enExample)
PL (1) PL4076461T3 (enExample)
PT (1) PT4076461T (enExample)
RS (1) RS67890B1 (enExample)
SI (1) SI4076461T1 (enExample)
SM (1) SMT202600134T1 (enExample)
WO (1) WO2021127572A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9428506B2 (en) 2012-04-14 2016-08-30 Intra-Cellular Therapies, Inc. Substituted pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines for the treatment of nervous system disorders
WO2019178484A1 (en) 2018-03-16 2019-09-19 Intra-Cellular Therapies, Inc. Novel methods
SMT202600133T1 (it) 2018-03-23 2026-05-12 Intra Cellular Therapies Inc Composti organici
AU2019328528B2 (en) 2018-08-31 2025-01-23 Intra-Cellular Therapies, Inc. Novel methods
JP2022549335A (ja) 2019-09-25 2022-11-24 イントラ-セルラー・セラピーズ・インコーポレイテッド 新規方法
IL297333B2 (en) * 2020-04-17 2025-09-01 Honeybrains Llc Preparations and methods for treating neuropsychiatric disorders
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000077001A1 (en) 1999-06-15 2000-12-21 Du Pont Pharmaceuticals Company Substituted heterocycle fused gamma-carbolines
US6713471B1 (en) 1999-06-15 2004-03-30 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
US7071186B2 (en) 1999-06-15 2006-07-04 Bristol-Myers Squibb Pharma Co. Substituted heterocycle fused gamma-carbolines
MX394214B (es) 2007-03-12 2025-03-24 Intra Cellular Therapies Inc Sintesis de gamma-carbolinas fusionadas con heterociclo substituido.
CA2719824A1 (en) * 2007-08-01 2009-02-05 Medivation Neurology, Inc. Methods and compositions for treating schizophrenia using antipsychotic combination therapy
ES2530090T3 (es) 2008-03-12 2015-02-26 Intra-Cellular Therapies, Inc. Sólido de gamma-carbolinas fusionadas con heterociclo sustituido
CA2725342C (en) 2008-05-27 2024-02-20 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines for sleep disorders and other disorders
KR102967223B1 (ko) * 2013-12-03 2026-05-19 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
KR20220054908A (ko) 2014-04-04 2022-05-03 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
JP7013454B2 (ja) * 2016-10-12 2022-02-15 イントラ-セルラー・セラピーズ・インコーポレイテッド アモルファス固体分散体
CA3082834A1 (en) * 2017-11-22 2019-05-31 Concert Pharmaceuticals, Inc. Deuterated analogs of d-serine and uses thereof
WO2019102240A1 (en) * 2017-11-27 2019-05-31 Egis Gyógyszergyár Zrt. Method for the manufacture of lumateperone and its salts
WO2019178484A1 (en) 2018-03-16 2019-09-19 Intra-Cellular Therapies, Inc. Novel methods
WO2020047408A1 (en) * 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
WO2020112941A2 (en) * 2018-11-27 2020-06-04 Teva Czech Industries S.R.O Solid state forms of lumateperone salts and processes for preparation of lumateperone and salts thereof

Also Published As

Publication number Publication date
EP4076461A4 (en) 2024-01-03
EP4744678A2 (en) 2026-05-20
JP7727634B2 (ja) 2025-08-21
JP2025166121A (ja) 2025-11-05
HRP20260406T1 (hr) 2026-05-08
JP2023507584A (ja) 2023-02-24
LT4076461T (lt) 2026-06-25
EP4744678A3 (en) 2026-07-22
DK4076461T3 (da) 2026-02-23
WO2021127572A1 (en) 2021-06-24
EP4076461B1 (en) 2026-01-28
PL4076461T3 (pl) 2026-04-27
SI4076461T1 (sl) 2026-05-29
EP4076461A1 (en) 2022-10-26
US20210186962A1 (en) 2021-06-24
RS67890B1 (sr) 2026-04-30
PT4076461T (pt) 2026-04-16
SMT202600134T1 (it) 2026-05-12
ES3067760T3 (en) 2026-05-25

Similar Documents

Publication Publication Date Title
JP2023507584A5 (enExample)
CN103945848A (zh) 被取代的喹唑啉酮的口服即释制剂
JP2011508765A5 (enExample)
CY1119663T1 (el) Φαρμακευτικη μορφη δοσολογιας για απο του στοματος χορηγηση ενος αναστολεα της οικογενειας bcl-2
JP7727634B2 (ja) 統合失調症処置方法
CY1108625T1 (el) Φαρμακευτικες συνθεσεις για τη χορηγηση απο το στομα ηπαρινης ή παραγωγων της
WO2002051442A1 (en) Concomitant drugs
AU2011221889A1 (en) Film preparation containing medicament with unpleasant taste
JP2025166121A5 (enExample)
AU2017244145A1 (en) Thiazolide compounds for treating viral infections
EA201071006A1 (ru) Набор, композиция, продукт или лекарственное средство для лечения нарушения познавательной способности
RU2018136580A (ru) Цитратная соль (s)-4-((s)-3-фтор-3-(2-(5,6,7,8-тетрагидро-1,8-нафтиридин-2-ил)этил)пирролидин-1-ил)-3-(3-(2-метоксиэтокси)фенил)бутановой кислоты
JP2019501879A5 (enExample)
EA201990249A1 (ru) Применение и режим дозирования терапевтических агентов при эндометриозе
AU2012326976B2 (en) Sustained-release preparation
WO2015140569A1 (en) Pharmaceutical composition
CN105530939A (zh) 骨质疏松症治疗剂
EA201600486A1 (ru) Фармацевтические композиции, включающие антикоагулянт n-(5-хлорпиридин-2-ил)-2-({4-[этанимидоил(метил)амино]бензоил}амино)-5-метилбензамид
EP3020399A1 (en) Novel pharmaceutical composition for preventing or treating cancer
EP3632447A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF BONE DISEASES
WO2020247758A1 (en) Compounds and methods for the treatment of parasitic infections
JPWO2020080451A1 (ja) 糖尿病腎症における腎線維化抑制剤
WO2017070355A1 (en) Response-guided hcv therapy
RU2010118458A (ru) Производное изоксазола для лечения рака
WO2014123355A1 (ko) 셀레콕시브 경구투여용 조성물